Omaveloxolone eased age-related inflammation in male mice
Experiments in aged male mice found that the drug reduced inflammatory changes, likely through effects on both inflammatory and antioxidant pathways.
Limit: Only 5 mice per group in the aging experiment
Edited by Boris Djordjevic · AgingResearch.News
In aged male mice, experiments with omaveloxolone reduced aging-related inflammatory changes. The drug lowered levels of STING, a protein involved in immune signaling, and suppressed inflammatory signaling downstream of it.
The researchers identified omaveloxolone through large-scale screening. Tests found that it bound to STING and changed its behavior in ways consistent with a less stable shape. The authors proposed that these changes helped an enzyme mark STING for breakdown by the cell’s protein-disposal machinery. Omaveloxolone also activates an antioxidant pathway. The authors said its benefits in mice likely reflected effects on both inflammatory and antioxidant pathways. The drug is already approved in the US for Friedreich’s ataxia, an inherited nervous system disease.
Why it matters
Abnormal STING activity is involved in aging-related inflammation. The authors’ framework points to changing this protein’s shape as a possible way to target that process.
Caveats
These animal experiments do not establish benefits in people, and the reported mouse results were limited to aged males. The abstract does not report the number of mice, dose or treatment duration.
The paper
Chinese Academy of Sciences
Nature Communications, Sep 17, 2026, Open access
